Bioverativ Therapetutics

Random entry RSS

Posted in:
Legal

The PTAB Denies Institution of Two IPRs Involving a Patent Directed to the Treatment of Hemophilia B
By Seth Cockrum January 31, 2019 Comments are off
The PTAB recently denied institution of two IPRs filed by CSL Behring LLC, CSL Behring GMBH, and CSL Behring Recombinant Facility AG...

Read more

Tagged with: Aprolix®, Bioverativ Therapetutics, BLA, CSL Behring, Idelvion®, IPR, PTAB

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus

Back to Top